Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> Lysostaphin [9011-93-2]

Lysostaphin [9011-93-2]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-P2329-5mg

Size : 5mg

Marke : MedChemExpress

Weitere Informationen anfordern

Contact local distributor :


Telefonnummer : +1 850 650 7790

Lysostaphin is an antistaphylococcal agent. Lysostaphin has activities of three enzymes namely, glycylglycine endopeptidase, endo-β-N-acetyl glucosamidase and N-acteyl muramyl-L-alanine amidase.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Lysostaphin Chemische Struktur

Lysostaphin Chemische Struktur

CAS. Nr. : 9011-93-2

This product is a controlled substance and not for sale in your territory.

Based on 1 publication(s) in Google Scholar

Alle Antibiotic Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam
Beschreibung

Lysostaphin is an antistaphylococcal agent. Lysostaphin has activities of three enzymes namely, glycylglycine endopeptidase, endo-β-N-acetyl glucosamidase and N-acteyl muramyl-L-alanine amidase[1].

In Vitro

Lysostaphin (16 µg/mL, 0-260 minutes) exerts its antibacterial effect by hydrolyzing the peptidoglycan cross-linkages of Staphylococcus aureus, weakening the mechanical strength of the cell wall and causing structural damage[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lysostaphin Related Antibodies
In Vivo

Lysostaphin (5 mg/kg, intravenous injection, once daily for 3 consecutive days) effectively clears systemic Staphylococcus aureus (MSSA) infections in CF-1 mice[2].
Lysostaphin (50 mg/kg, intravenous injection, single dose) effectively clears Staphylococcus aureus (MSSA and MRSA) infections from the kidneys, spleen, and liver, but is not superior to repeated lower doses[2].
Lysostaphin (1 mg/kg, intravenous injection, once daily for 3 consecutive days) combined with Oxacillin (HY-B0925A) achieves the same antibacterial effect with a lower concentration of Lysostaphin. When combined with Vancomycin, low-dose Lysostaphin (1 mg/kg) similarly shows enhanced efficacy against MRSA[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Systemic infection model in CF-1 mice induced by methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA)[2]
Dosage: 1, 5, 25, 50 mg/kg
Administration: Intravenous injection (i.v.), single high-dose administration: 25 mg/kg or 50 mg/kg intravenous injection, single dose; Once daily administration: 1 or 5 mg/kg, once daily for 3 days.
Result: Cleared MSSA from the blood and organs of mice (5 mg/kg for 3 days).
Cleared MSSA and MRSA from the kidneys, spleen, and liver (A higher single dose of 50 mg/kg).
Improved effectiveness and allowed reduction of the lysostaphin dose to 1 mg/kg for MRSA infections (Combined with Oxacillin (HY-B0925A) or Vancomycin (HY-B0671)).
CAS. Nr.

9011-93-2
Appearance

Solid

Color

White to off-white

SMILES

[Lysostaphin]
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation

COA (230 KB)

Handling Instructions (2659 KB)
Verweise

  • [1]. Jaspal K Kumar, et al. Lysostaphin: An Antistaphylococcal Agent. Appl Microbiol Biotechnol. 2008 Sep;80(4):555-61.  [Content Brief]

    [2]. Kokai-Kun JF, et al. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother. 2007 Nov;60(5):1051-9.  [Content Brief]

    [3]. Francius G, et al. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin. J Bacteriol. 2008 Dec;190(24):7904-9.  [Content Brief]

  • [1]. Jaspal K Kumar, et al. Lysostaphin: An Antistaphylococcal Agent. Appl Microbiol Biotechnol. 2008 Sep;80(4):555-61.

    [2]. Kokai-Kun JF, et al. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother. 2007 Nov;60(5):1051-9.

    [3]. Francius G, et al. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin. J Bacteriol. 2008 Dec;190(24):7904-9.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lysostaphin Related Classifications

  • Inflammation/Immunology Infection
  • Anti-infection
  • Bacterial Antibiotic

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lysostaphin9011-93-2BacterialAntibioticCF-1 miceAntibacterial effectStaphylococcus aureus (MSSA)Staphylococcus aureus (MRSA)Inhibitorinhibitorinhibit

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
HY-P2329-1mg
Lysostaphin [9011-93-2]
 1mg